

Case No. 09-50002(SMB)

Adv Pro. No. 17-01185(SMB)

Dear Judge Bernstein,

Thank you for your time in this most serious matter. This is my response to the defendant's counsel, Sullivan & Cromwell. I have read their notice of motion to dismiss and I'm rather disturbed. The motion focuses just on the bankruptcy Chrysler filed on April 30th 2009. During this time they had a partnership with Fiatt which was actually formed between the two companies that had a non-binding term sheet to form A global alliance on January 20th 2009.

My question is how this bankruptcy is relevant to my wreck and injuries sustained from 2009. I now will show factual proof that the defendant is guilty of a Wanton act under the Tort law. It doesn't matter if the incident was before, during, or after the bankruptcy, for according to the Tort law mentioned by the defendants lawyer their client willfully witheld the MSDS sheet I requested. As a result, I didn't recieve the proper medical treatment. At that time my doctors did the best they could without the proper information. My injuries from the wreck are from the chemicals in the defendant's air bag that they made. Most of my injuries are permanent with no cure.

I'd like to address a matter that counsel has brought to the attention of this court. The defendants stated that I didn't file until sometime after my injuries. That is incorrect your honor. I first filed a claim with Chrysler on Jan 2, 2009. They assigned me a claim case number which is 1821-6088. When I did make contact with Chrysler they put me in contact with Chuck Fischer. Your honor I did make contact with Chrysler and they sent a team of specialists to inspect the car in January 2009. They informed me that there were no recalls on that car and that the driver's side airbag tore half a dollar piece size in the middle. They're claiming that the chemical was talc powder, but according to their MSDS sheet thats a lie. The MSDS sheet shows toxic chemicals yes poisons contained in their airbag. As a result of being exposed I received the following injuries some of which are permanent with no cure. An again I have factual proof as to what I have stated.

Injuries are as follows:

Second degree chemical burns to my face, scalp, and chest. Causing red rashes to

appear on my face and chest without notice thus being labeled by doctors as flare ups. Nothing can be done either to prevent this.

Trauma induced glaucoma to both eyes having the tear ducts ripped out of both eyes with partial vision loss. Prognosis drops daily and possible operations to relieve the pressure to slow down the condition which has no cure for it either.

Damaged airways which include the lungs, throat, esophagus and upper gi tract. In regards to the lungs the air sacs have tilted and some have collasped. The chemicals in the airbag shows how it does affect the upper respiratory and the lungs. As a result of this I am and will continue to be under the care of a global specialist at Barnes Hospital in Missiouri. The M.S.D.S. sheet shows the toxic chemicals I was exposed too. It caused me to develop high blood pressure labeled as pulmonary hypertension. In March I had a mini stroke due to this. Also, this caused white spots on the left side of my brain. I also developed bradycardia which I didn't get until after chemical exposure.

Mental anguish:

Has affected job opportunities due to physical limitations. Not able to continue career which caused financial hardship.

I finally accepted that I can't do certain jobs so I recently applied for disability which I hate.

And I am sorry I have never been a vain person but there is nothing more depressing then to look into the mirror and one day your face is normal and the next day your face looks and feels like you're on fire like a bad sunburn. I also have enclosed pictures as proof to this which still continues today.

My future now consists of many medical providers until the day I die and I dont know what is going to happen next from what dwells in my body. For I feel like a walking time bomb and God only knows what that stuff will do. I never planned for my life to be like this and now all I can do is treat the symptoms as they come. The unknown is the cold hard facts in regards to my health.

So now I would like to take this time to thank you and your court for taking the time to hear this. I appreciate and respect the decision that your honor will pass down through your ruling and to counsel. All I seek is the truth and for justice to be served. I hope and pray that after you review the defendants response back, that we can finally end this once and for all.

Thank You, Shelley Goodall



Customer Claims Resolution Group

January 12, 2009

Via U.S. Mail

Shelly M Burg 3014 S. 12th Street Springfield, IL 62703

Re: 1996 Chrysler Sebring Jxi VIN: 3C3EL55HXTT269546

Dear Shelly M Burg:

Thank you for contacting Chrysler LLC and raising concerns that you have with the above referenced vehicle. We are always concerned to hear of injuries and accidents involving our customers and their vehicles.

Chrysler LLC conducted an investigation into the incident and inspected the vehicle. Specifically, the inspector found no problems with the subject's air bag system. Air bags do not contain any chemicals. The burns you sustained were caused by the the 200 mph force of the deploying air bag. This is the amount of force madadted by Federal law. The powder you noticed was a talc powder that is used so that the folds of the air bag do not stick together. This talc is neccessary so that when needed, the air bags will deploy correctly, as they did in your accident.

I have enclosed an informational brochure pertaining to air bag systems should you have any further questions. In addition, Chrysler LLC notes the following website that contains uselful consumer information on air bag safety and includes animations on how they function during an accident: http://www.safercar.gov/air.htm

Again, we are sorry to hear of your injuries and sincerely hope that you are well on the road to recovery.

Thank you again for raising your concerns with Chrysler LLC.

Very truly yours,

Customer Claims Resolution Group Office of the General Counsel

Enclosure

The second of th



Customer Claims Resolution Group

January 07, 2009

MS SHELLY M BURG 3014 S 12TH ST SPRINGFIELD, IL 62703-4110

Dear MS BURG;

Thank you for contacting Chrysler LLC regarding your 1996 CHRYSLER SEBRING JXI 2-DOOR CONVERTIBLE, VIN: 3C3EL55HXTT269546. We are currently in the process of reviewing your file. Our records, at this time, indicate the following information regarding your vehicle:

CAIR Number:

18216088

Current Owner:

MS SHELLY M BURG

Purchased Used:

YES

Date of Purchase:

01/28/2008

Incomplete Recalls:

NONE

If any of this information requires updating, please notify us at the following (toll free) number: 1-888-922-7329.

As we proceed with our review, one of our representatives may need to contact you for additional information about your vehicle.

For information, we expect to inform you of our decision within the next 12 business days. If you do not hear from us by then, please contact us (toll free) at: 1-888-922-7329.

Note: If you have already settled with your insurance company, please notify us immediately at our 1-888-922-7329 (toll free) number.

Thank you for your cooperation.

Customer Claims Resolution Group

Center for Advanced Medicine 314-454-8917 1-877-888-5864

RETUI	RN INST	TRUCTIONS:									COI	PAY	Disc./A.E.
		PHYSICIAN	VISIT:	DFL	EXI	BLE		☐ NOT FLEX	IBLE		\$ MC	NISA	Cash Check#
Day of Week Monday		Tuesday				Wednesday	Thurs	Thursday			Friday + + + + + + + + + + + + + + + + + +		
Weeks 1		1	2			3	4		T		5 6		
	Mon	ths	1		2			3	4	101	V 1		6 (12)
	AUT	DIMMUNE LABS					I	PFT'S			IM	MU	NE SYSTEM LABS
Today	Return			Today	Next Avail.	Return				Toda	-	turn	
		Aldolase						ABG					Aspergillus Antigen Panel,
		ANA comprehensive Panel						☐ Resting			+		Hypersensitivity pneumonitis Avian Antigen Panel,
		ANCA Screen w/ reflex to MPO, PR	500000000000000000000000000000000000000					☐ Exercise					Hypersensitivity pneumonitis
		CCP Ab, IgG-Cyclic Citrullinate						☐ F1O2					General Hypersensitivity pneumonitis
		CK-creatine kinase, total plasma						DLCO			_	- '	Antigen Panel
		Double Stranded DNA, Quant, I	Blood					Lung Volumes			_		IgA Quant, Serum - Immunoglobulin A
		ENA screen			_		-				_		gM Quant, Serum - Immunoglobulin M
		Myomarker Panel 3						MIP/MEP		믐	-		IgE Quant, Serum - Immunoglobulin E
		Rheumatoid Factor, RF			-			Other		님	-	-	lgG Quant, Serum - Immunoglobulin G lgG Subclasses
		SCL70 antibodies, IgG, serum						Methacholine Challenge (MC	CC)				RADIOLOGY
		IC PULM LABS						Pulse Oximetry O2 Assessme	ent	Today	Next Avail.	Return	The second desired to the second seco
Today	Return					100	DE:	Spirometry					Bone Density DXA-Hip and Spine
		Alpha-I Antitrypsin, Deficiency Pr	ofile				-	Supine		-		0.000	77080 - Bone Health
		BMP Random, Plasma						☐ Weekly SPI	- 1				Cardiac MRI (PH Protocol)
		BNP, B-type Natriuretic Peptide		2003 1	10000	2011/2012		☐ With Bronchodilator					CT Angio-Venogram w & wo (PAVM)
		CBC with differential and Platet											CT Angio-Venogram w & w/o (PAVM) I
		CMP Random, Plasma				12		Without Bronchodilator					☐ CT Chest
		Ferritin, Serum					O	THER					☐ BT Protocol
	-	Iron Profile		Today	Next	n .		* USE (2.01)	N. S. William				☐ High Resolution w/o Contrast
		PT and PTT		Today	Avail.	Return	1						☐ National Lung Screening Protocol
		PT INR, plasma											PE Protocol with Contrast
													☐ With Contrast
		Thyroid Cascade profile (TSH/T4)				-	-	Flu Vaccine					☐ Without Contrast
		Vitamin D, 25 Hydroxy					-	Hep A Vaccine					CXR PA & Lateral
		Vitamin A						Hep B Vaccine					Fluroscopy, Alone (Sniff Test)
		Vitamin E						Nucala		-			
		Other					_	Pneumovax					☐ V/Q Lung Scan ☐ Quantitative
	MICE	OBIOLOGY LAI) C					Prevnar Vaccine		-		-	
	MICH	ODIOLOGI LAI	33					Skin testing (Monday's only)					2-D Echocardiogram w/ Doppler & Colorff Bubble Study-Eval For Shunt
Today	Return		4					Sleep Study Referral					Estimation of PA Pressure
		ABPA - Allergic Bronchopu	Imonary					Volair					☐ No Contrast / Contraindicated
		Aspergillosis Cascade	//	7/2	111	-			/		,	PD A	NCDI ANIET ADC
		Sputum (See ATT)		116	111				\			IKA	NSPLANT LABS
-	-	HIV 1/2 Abs, with reflex					1.	20 DET	. \	Today	Ret	turn	
		Streptococcus Pneumoniae I	gG AB				1 :	JU 11 1			+-	J [Cyclosporine A Through, Blood
		23 Serotypes					0.	n n A	/		-	5 1	CMV - Cytomegalovirus PCR Quant, Bloo
							16.	DO CHOIC			-		Everolimus, Blood
Diag	nosis fo	or Testing / Appl Inf	ormation	/Pt In	nstru	ction	S	VIIII	/	7/2 7/3			Prograf - Tacrolimus - Fk506,
		/ - //	()	1		1					-]	Whole Blood, Random
	100	west finding		1 1 21 1	1	1 3	44						Sirolinus - Rapanune LC, Blood
<u></u>	a .												
	OH	HLBUTER	FOL	2	PLI	FF:		EUEFY 1	1+00	120	/	1-	1488788
		1			1	กกุค	_	314-273	-1115	7			
					_/1	11/1/1	_	217 a 1 3	-145	7			
			-										
PHYS	ICLANS	IGNATURE:											
11110	TO LIVE OF	COLOR LONG.											

St. Louis, MO **GOODALL**, SHELLEY M July 22, 1968 Female 13440708 Patient Id 317 E LINCOLN ST (217) 691-0337 English (preferred) EDINBURG, IL 62531-9432 Home Phone Address White Race Not Hispanic or Latino Ethnicity Visit Summary Plan of Care Planned Observations Planned Goals not documented Vital Signs 22-July-2016 12:57 PM BP Systolic 127 mm(Hg) Comments: Location: LUE; Position: Sitting **BP Diastolic** 85 mm(Hg) Comments: Location: LUE; Position: Sitting Temperature 98.6 f Comments: Method: Oral **Heart Rate** 79 /min **Physical Findings** 18 Comments: Respiration Height 63.5 in Weight 256 lb 44.64 kg/m2 Body Mass Index Calculated Body Surface Area Calculated 2.16 m2 Physical Findings Comments: O2 Saturation Medications Medication not documented Medications Administered **Medication Administration not documented Problems** Chemical exposure Allergies and Adverse Reactions Allergy history not documented Results Results not documented **Procedures** Procedures not documented Social History Smoking Status Former smoker

Encounters

MEDICAL REPORT

Frederick M. Rauscher, M.D.

FROM:

	Prairie Eye Center 2020 W. Iles Ave. Springfield, IL 62704-4174
TO:	Shelly M. Burg 7 Prairie Lane Court Springfield, IL 62704
YOUR OPIN	POND TO THE FOLLOWING QUESTIONS IN THE SPACES PROVIDED. IF HONS ON THESE MATTERS CANNOT BE FAIRLY RELFECTED IN THIS LEASE PROVIDE A NARRATIVE REPORT.
	state the condition or complaints for which you are treating this patient. INDUCED GLAUCOMA BOTH EYES
Life leng. but freque	estate the treatment for the condition or complaints of this patient. Ireatment with cyclops (She is on twice a day treatments now cency & # of draps is likely to mulase own Home to prevent won of glalucoma & visualloss). These conditions caused, aggravated or accelerated in their onset or progression by the
accide	Stres [] No [] Unknown New visible damage to the drainage angle in both eyes visual field defects in both eyes (progressive loss)
Should Not	e state the prognosis. emain 5 tuble (10-15% Visual field 1055 in each eye) integrate with treatment. Will deflice rate without freatment further treatment or diagnostic procedures, if any, do you recommend for the injuries which
this no	atient has suffered? y eyedraps, Visual field + eye (xammation why lo morths

Page 2	2
6. 	ANY ADDITIONAL COMMENTS: attent is very compliant with her eyedrops and I would therefore exploit her progress's to be good (assuming continue good compliance & continued months my for future worseness of her glaucoms).
	derick M. Rauscher, M.D., certify that I have provided the answers set forth in the report above, and nese answers represent my opinions within a reasonable degree of medical certainty.

09-50002-mg Doc 8507 Filed 02/16/18 Entered 02/16/18 15:38:53 Main Document Shelly M. Burg Pq 8 of 38

DATE: 12/2/2010

Frederick M. Rauscher, M.D.
Prairie Eye Center

Pulmonary Function Test Order Form Physicians Group Associates PFT Lab 2901 Old Jackson File Road Springfield, 8, 62704

290	1 Old Jacksonville Road Springfield, 8, 62704 Tel: 217-698-9722
Patient Name	DOB 7-22-6.8
Phone Number Hom	9539-237/ Cell 99/ 6385 Work
Date	2009
Carl Lawyer, MD	Healthy Women's earn
L'air	1:07 mg 2-4-09
	Carlenger," PFS
	-T- Cohon at onl
☐ Full PF	
ivietnach (if FEV1 allow	oline Challenge Test
(1) LEA I SHOW	s) Work was those
Dx:	
798.05 (duan-in-)	- Marine Marine
786.05 (dyspinea) 786.2 (cough)	17-16-09
493.90 (asthma) 496 (COPD)	100
416.9 (cor pulmonale)	9'00
(other)	
•	
	Carl Lawyer N.D.
• • • • • • • • • • • • • • • • • • •	
To schedule call 698-	9722 extension 353

GOODALL, SHELLEY

MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: WITKOP, PHILIP D, MD

Acct: Y00001782705 Pt Type: REG ER Ord Site: MAIN

Study Date 04/04/16

Accession # 0404-0105

Procedure Code A-CHESTPE Procedure

CTA Chest Pulmonary Embolism

*** Signed ***

Date: 4/4/2016.

Exam: CT chest.

Comparison: CT chest dated 3/30/2016.

Technique: Thin section images were obtained of the chest with a CTA pulmonary embolism protocol. 50 mL of Isovue-370 through an existing IV site in the left antecubital fossa. Coronal and sagittal reconstructions. Coronal 3-D MIP reconstructions. A dose lowering technique was used for this procedure, which may include, but is not limited to, dose reduction technique, automated exposure control, the use of Iterative reconstruction, and ALARA (As Low As Reasonably Achievable)/ Image gently techniques.

History: History of pneumonia on antibiotics. Continued shortness of breath, cough. Slight hemoptysis.

Findings:

CHEST: The heart size is normal. The thoracic aorta is normal without aneurysm nor dissection. There are no filling defects within the 4 chambers of the heart. The pulmonary arteries are patent without evidence of pulmonary embolism. There is no lymphadenopathy in the chest. The tracheal and main bronchial airways are patent. There are persistent, but somewhat improved opacities involving the left lower lobe indicating slightly improved pneumonia. There are new rounded nodules involving the superior left lower lobe possibly due to rounded organizing pneumonias given the short interval appearance. The largest nodule in the superior left lower lobe measures 1.9 cm as seen on series 15 image 74. There is a new subpleural nodule measuring 1.4 cm in the medial right lung base as seen on series 15 image 109. This is new since the prior examination and also is possibly nodular type pneumonia. CT surveillance imaging is recommended. There are no pleural effusions.

Visualized upper abdomen: The visualized portions of the liver, spleen, pancreas, adrenal glands and upper kidneys appear normal. The gallbladder surgically absent.

Osseous structures: There is straightening of the spinal column, but no destructive osseous lesion. There is minimal spondylosis in the thoracic spine.

CC: () Fax:

Printed On: 04/04/16 1 of 2

GOODALL, SHELLEY

MRN: MA00465664

Impression:

1. No pulmonary embolism. The pulmonary arteries are patent.

2. Slightly Improved pneumonia in the left lung base. However, there are new nodules in the superior left lower lobe and posterior medial right lower lobe. These are thought to represent nodules of organizing pneumonia given the short interval appearance. Septic pulmonary emboli, early abscesses and atypical mycobacterial infection are not excluded, but are lesser differential diagnostic considerations.

Electronically Signed By: STANTON, DANIEL L MD 04/04/16 1742

Dictated On: 04/04/16 1711
Interpreted By: STANTON, DANIEL L MD
Transcribed On: 04/04/16 1716 - INFCE

CC: WITKOP,PHILIP D, MD

CC: () Fax:

Printed On: 04/04/16

BURG, SHELLY MAE MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: GAINES, SAM, MD

Acct: Y00001242108 Pt Type: REG ER Ord Site: MAIN

Study Date 01/11/14

Accession # 0111-0062

Procedure Code

Procedure

CXR2V

XR Chest 2 View

*** Signed ***

Examination: Chest 2 view

Exam time: 1:05 AM

Clinical history: Chest pain

Comparison: 11/20/2013

Technique: PA and lateral chest heart size and pulmonary vasculature are within

normal limits. No infiltrate. No effusion. Lungs do not appear

Findings: Hyperinflated. - Lungs

IMPRESSION:

1. No radiographic evidence of active disease the chest.

Electronically Signed By: GLEASON, THEODORE J, MD 01/11/14 0131

Dictated On: 01/11/14 0130

Interpreted By: GLEASON, THEODORE J, MD Transcribed On: 01/11/14 0130 - INFCE

CC:

BLAND, GEOFFREY A, MD

GAINES, SAM, MD

CC: () Fax:

Printed On: 01/11/14 1 of 1

GOODALL, SHELLEY MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: BEAL DAVID D MD. RES

Acct: Y00001779876 Pt Type: REG ER Ord Site: MAIN

Study Date

Accession #

Procedure Code

Procedure

03/30/16

0330-0060

A-CHESTPE

CTA Chest Pulmonary Embolism

*** Signed ***

Date: 3/30/2016.

Exam: CT chest.

Comparison: CT chest dated 4/20/2011.

Technique: Thin section images were obtained of the chest with a CTA pulmonary embolism protocol. 50 mL of Isovue-370 through an existing IV site left antecubital fossa. Coronal, sagittal and coronal 3-D MIP reconstructions. A dose lowering technique was used for this procedure, which may include, but is not limited to, dose reduction technique, automated exposure control, the use of iterative reconstruction, and ALARA (As Low As Reasonably Achievable)/ Image gently techniques.

History: Blood-tinged sputum. Postnasal drip. Heart catheterization yesterday.

Findings:

CHEST: The heart size is normal. The thoracic aorta is normal without aneurysm nor dissection. The central pulmonary arteries are patent. The bolus timing is suboptimal for evaluation of the mid and peripheral pulmonary arteries. There is no lymphadenopathy in the chest, but there are borderline likely reactive lymph nodes in the left infrahllar region and AP window.. The tracheal and main bronchial airways are patent. There are opacities involving the left lower lobe basilar portion. This is worrisome for pneumonia and possibly aspiration pneumonia. There is air trapping throughout the lungs in general. The left upper lobe and right lung are relatively clear. There are no pleural effusions. There is motion artifact degrading evaluation for pulmonary nodules.

Visualized upper abdomen: The visualized portions of the liver, spleen, pancreatic tail and adrenal glands appear normal.

Osseous structures: The osseous structures are grossly normal other than mild spondylosis in the thoracolumbar junction.

Impression:

- 1. Suboptimal bolus timing for evaluation of pulmonary embolism. There are no central pulmonary emboli, but the mid and peripheral pulmonary arteries cannot be assessed. If there is persistent clinical concern for pulmonary embolism, would consider VQ scan or repeat CT chest.
- 2. Pneumonia in the left lower lobe. Cannot entirely exclude concomitant pulmonary hemorrhage given the history of hemoptysis.

CC: () Fax:

1 of 2 Printed On: 03/30/16

09-50002-mg Doc 8507 Filed 02/16/18 Entered 02/16/18 15:38:53 Main Document Pg 14 of 38

St. John's Hospital Springfield, Illinois Department of Radiology

GOODALL, SHELLEY

MRN: MA00465664

3. Borderline reactive lymphadenopathy in the left infrahilar region and left AP window.

4. Mild air trapping.

Electronically Signed By: STANTON, DANIEL L MD 03/30/16 1440

Dictated On: 03/30/16 1432

Interpreted By: STANTON, DANIEL L MD Transcribed On: 03/30/16 1432 - INFCE

CC:

BEAL, DAVID D MD, RES BLAND, GEOFFREY A, MD

CC: () Fax:

Printed On: 03/30/16

2 of 2

GOODALL, SHELLEY

MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: STEVENS, JANDA T MD

Acct: Y00001790980 Pt Type: REG ER Ord Site: MAIN

Study Date

Accession #

Procedure Code

<u>Procedure</u>

04/16/16 0416-0022

ABDPELWC

CT Abdomen Pelvis W

*** Signed ***

4/16/2016, 7:31 AM.

HISTORY: Epigastric pain radiating to the back. Squeezing pain. Nausea. Prior laparoscopic cholecystectomy.

EXAM: CT imaging of the abdomen pelvis was performed after the intravenous and ministration of 100 mL Isovue 370 contrast. Imaging was performed utilizing radiation dose reduction imaging techniques. Correlation is made to study 8/29/2015.

FINDINGS: There are a few very small patches of infiltrate or atelectasis at both lung bases. No pulmonary consolidation at the lung bases. The heart size is within normal limits. No pericardial effusion. No pleural effusion.

No evidence of mass or enlargement of the liver, spleen, pancreas nor either adrenal gland. Gallbladder is absent with surgical clips gallbladder fossa consistent with prior cholecystectomy. No bile duct dilatation. Both kidneys function. No renal parenchymal mass. No dilatation of the intrarenal collecting system of either kidney and no evidence of obstructive uropathy. No retroperitoneal mass or adenopathy. No bowel distention and no evidence of bowel obstruction. The appendix and terminal ileum appear normal. 6.7 cm right ovarian cyst which has developed since the previous study. Small left ovarian cyst. Nabothian cysts in the cervix. No lateral pelvic mass or adenopathy. No ascites.

IMPRESSION:

New 6.7 cm right ovarian cyst. Small left ovarian cysts or follicles. Small nabothian cysts in the cervix. Diffuse very small areas of faint patchy infiltrate or atelectasis at the lung bases.

Electronically Signed By: GREGG, GREGORY A, MD 04/16/16 0808

Dictated On: 04/16/16 0759

Interpreted By: GREGG, GREGORY A, MD Transcribed On: 04/16/16 0759 - INFCE

CC:

STEVENS, JANDA T MD

CC: () Fax:

Printed On: 04/16/16

GOODALL, SHELLEY MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: WITKOP, PHILIP D, MD

Acct: Y00001782705 Pt Type: REG ER Ord Site: MAIN

Study Date 04/04/16

Accession # 0404-0105

Procedure Code A-CHESTPE <u>Procedure</u>

CTA Chest Pulmonary Embolism

*** Signed ***

Date: 4/4/2016.

Exam: CT chest.

Comparison: CT chest dated 3/30/2016.

Technique: Thin section images were obtained of the chest with a CTA pulmonary embolism protocol. 50 mL of Isovue-370 through an existing IV site in the left antecubital fossa. Coronal and sagittal reconstructions. Coronal 3-D MIP reconstructions. A dose lowering technique was used for this procedure, which may include, but is not limited to, dose reduction technique, automated exposure control, the use of iterative reconstruction, and ALARA (As Low As Reasonably Achievable)/ Image gently techniques.

History: History of pneumonia on antibiotics. Continued shortness of breath, cough. Slight hemoptysis.

Findinas:

CHEST: The heart size is normal. The thoracic aorta is normal without aneurysm nor dissection. There are no filling defects within the 4 chambers of the heart. The pulmonary arteries are patent without evidence of pulmonary embolism. There is no lymphadenopathy in the chest. The tracheal and main bronchial airways are patent. There are persistent, but somewhat improved opacities involving the left lower lobe indicating slightly improved pneumonia. There are new rounded nodules involving the superior left lower lobe possibly due to rounded organizing pneumonias given the short interval appearance. The largest nodule in the superior left lower lobe measures 1.9 cm as seen on series 15 image 74. There is a new subpleural nodule measuring 1.4 cm in the medial right lung base as seen on series 15 image 109. This is new since the prior examination and also is possibly nodular type pneumonia. CT surveillance imaging is recommended. There are no pleural effusions.

Visualized upper abdomen: The visualized portions of the liver, spleen, pancreas, adrenal glands and upper kidneys appear normal. The gallbladder surgically absent.

Osseous structures: There is straightening of the spinal column, but no destructive osseous lesion. There is minimal spondylosis in the thoracic spine.

CC: () Fax:

Printed On: 04/04/16

GOODALL, SHELLEY MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: GOLDBERG, DENNIS J MD

Acct: Y00001781515 Pt Type: REG ER Ord Site: MAIN

Study Date 04/01/16

Accession # 0401-0030

Procedure Code BRNW+WOC Procedure
MRI Brain WWO

*** Signed ***

INDICATION: Right-sided numbness. History of TIA.

EXAMINATION: MRI brain with and without contrast.

TECHNIQUE: Sagittal and axial T1, and axial T2, FLAIR, gradient (T2*), and DWI Images with ADC map reconstructions obtained. Additional axial and coronal post contrast T1 images were obtained after administration of 23 mL MultiHance intravenously without adverse event.

COMPARISON:

Head CT 4/1/2016. MRI 3/8/2016.

FINDINGS:

There is no diffusion restriction or evidence of acute infarct. There is no evidence of intracranial mass, mass effect, or midline shift. Postcontrast images reveal no abnormal intracranial enhancement. There are a few tiny punctate foci of FLAIR/T2 hyperintensity noted in the frontal deep white matter, nonspecific. The ventricles and extra-axial/subarachnoid spaces are symmetric and normal in appearance. No abnormal extra-axial collections. Proximal portions of the major intracranial arterial flow voids are visualized and appear grossly patent. No hemorrhagic foci of susceptibility seen on gradient echo images. Craniocervical junction, sellar content, and pineal region are unremarkable. Mastoid air cells and paranasal sinuses are clear. Visualized orbits are unremarkable.

IMPRESSION:

- 1. No acute intracranial abnormalities identified. No evidence of intracranial mass, abnormal enhancement, or acute infarct.
- 2. Few tiny nonspecific white matter abnormalities, possibly related to mild small vessel disease.

Electronically Signed By: BEKKER, SIMON V MD 04/01/16 1641

Dictated On: 04/01/16 1630

Interpreted By: BEKKER, SIMON V MD Transcribed On: 04/01/16 1630 - INFCE

CC:

BLAND, GEOFFREY A, MD GOLDBERG, DENNIS J MD

CC: () Fax:

Printed On: 04/01/16 1 of 1

GOODALL, SHELLEY

MRN: MA00465664 DOB: 07/22/1968

Sex: F

Ordering MD: STEVENS, JANDA T MD

Acct: Y00001790980 Pt Type: REG ER Ord Site: MAIN

Study Date

Accession #

Procedure Code

Procedure

04/16/16 0416-0022

16-0022 ABDPELWC

CT Abdomen Pelvis W

*** Signed ***

4/16/2016, 7:31 AM.

HISTORY: Epigastric pain radiating to the back. Squeezing pain. Nausea. Prior laparoscopic cholecystectomy.

EXAM: CT imaging of the abdomen pelvis was performed after the intravenous and ministration of 100 mL Isovue 370 contrast. Imaging was performed utilizing radiation dose reduction imaging techniques. Correlation is made to study 8/29/2015.

FINDINGS: There are a few very small patches of infiltrate or atelectasis at both lung bases. No pulmonary consolidation at the lung bases. The heart size is within normal limits. No pericardial effusion. No pleural effusion.

No evidence of mass or enlargement of the liver, spleen, pancreas nor either adrenal gland. Gallbladder is absent with surgical clips gallbladder fossa consistent with prior cholecystectomy. No bile duct dilatation. Both kidneys function. No renal parenchymal mass. No dilatation of the intrarenal collecting system of either kidney and no evidence of obstructive uropathy. No retroperitoneal mass or adenopathy. No bowel distention and no evidence of bowel obstruction. The appendix and terminal ileum appear normal. 6.7 cm right ovarian cyst which has developed since the previous study. Small left ovarian cyst. Nabothian cysts in the cervix. No lateral pelvic mass or adenopathy. No ascites.

IMPRESSION:

New 6.7 cm right ovarian cyst. Small left ovarian cysts or follicles. Small nabothlan cysts in the cervix. Diffuse very small areas of faint patchy infiltrate or atelectasis at the lung bases.

Electronically Signed By: GREGG, GREGORY A, MD 04/16/16 0808

Dictated On: 04/16/16 0759

Interpreted By: GREGG, GREGORY A, MD Transcribed On: 04/16/16 0759 - INFCE

CC:

STEVENS, JANDA T MD

CC: ()

Printed On: 04/16/16 1 of 1

09-50002-mg \	B507 FIII	ed 02/16/18 Pg 19	entered 02/16	15:38:53 Ma		
		KLINĞL	ER DERM			ناير.
M.D. Chart Review	/0V			Ŀ	7 P N	by. A. M.
INS.	INS SULT	FROM:	CONSULT TO:		iek fuk;	/
1-12-00	50 00	8	1,		gan 196 7	
DATE: 1-13-09 NAMI	<u>:: Melle</u>	ource		- RON	Kanosk	<u> </u>
Appointment 400 390	Π: <u>/2.</u> λ_ c	Contact Time	Return Visit	pm days_	months	weeks
Problem #Duration	nSig	ıns/SX	Has Tried	Severity		
1) pt. had Tar					·	
- for	a Can	accident	on 1-1-09	- huma	canef	con_
		einair				
			Les to be C			·
- Che	s see if	this	ill impror	بو		
3						
1000	un c	Biole)		Chripler	contac	}
				Chuck	. Fisher	~~~~
4_				1-634	-978-47	<u>30 </u>
Atternery	Ron	Kanto	Men			
	marlay	Jan Jan	my New	y - upi	<i>v</i> 5	
	<u> </u>					
-now notes	Seepy.	У	··········	<u> </u>	<u> </u>	
				PM Complete 48	49 81	
Update and Review (HPI, R of	S, P, F, S Hx)	- (9-01 Date	1-13-07	82	83 84	
Status Diagnosis		Location	Size		LIQ. N	Ŀ RX SEC
MCR O Almana						J
NCR RODOCC	melany to	Contact	dernotiti	v - See es	can !	7
NCR		····			[-
					[7
NCR					0	J
NCR			<u></u>		 (3
ICR						J
					(כ
ICR					(3
VCR						7
NCR	· · · · · · · · · · · · · · · · · · ·				6	J
NCR					0	3
Additional DX: Seb Ker Multiple:		Lentigo Multiple:	C	herry Angloma Multipl	e:	
PLAN:	NEEDS LFTS	: NEXT VISIT:		FOLLOW VISIT	:	
A.) Soepandusut	e wash					
B=0 #)						
					·	
						
			ST CARD SENT	Note Or-	2 n	WH
		FOR RFF	VALUATION	Note Staff	Provider	

Log Out

÷

This system includes: Buick, Cadillac, Chevrolet, Geo, GMC, Hummer, Isuzu, Suzuki, Saab, Saturn, Pontiac, Oldsmobile, Chrysler, Dodge,
Eagle, Jeep, Plymouth from 1980-2014,
Ford, Lincoln, Mercury, and Mazda Trucks from 1992-2012,
Mercedes from 1981-2009, and Hyundai 1981-2012

Flicel a 41	i idaliibei	to begin.	
	Search		

Enter a VIN Number to begin

Report for VIN: 3C3EL55H5TT282446

- 3: Built by Chrysler De Mexico
- C: Chrysler
- 3: Passenger Car
- E: Manual Seat Belts/ Driver & Passenger Air Bags
- L: Sebring JXi (JX-P-27 Conv.)
- 5: Premium (P)
- 5: 2 dr. Convertible/Open Body
- H: 2.5L V-6 Gasoline (SFI) SOHC (EEB)
- 5: Check Digit
- 1: Toluca Assembly (Toluca, Mexico)

Body Code: JXCP27

Engine: EEB 2.5L V6 SOHC 24V SMPI ENGINE

Transmission: DGL 4-SPEED AUTOMATIC TRANSMISSION

Build Date: April 12, 1996

Code	Description
*RL	LEATHER TRIMMED BUCKET SEATS
-K5	INTERIOR CAMEL

09-50002-mg Doc 8507 Filed 02/16/18 Entered 02/16/18 15:38:53 Main Document Pg 21 of 38



MATERIAL SAFETY DATA SHEET


PRODUCT NAME

POTASSIUM NITRATE

Product Code: Date of issue:

001/05-115 March 2012

Supersedes: October 2008



The following symptoms may occur:

In case of inhalation Irritation to respiratory tract

Delayed lung effects after short term exposure to thermal degradation products

In case of skin contact In case of eye contact

May cause redness or irritation May cause redness or irritation

In case of ingestion

Ingestion of large amounts may cause:

Gastrointestinal disturbances

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

FIRE FIGHTING MEASURES

Flammable properties

Not flammable.

Extinguishing media

Suitable extinguishing media:

Use any suitable mean for extinguishing surrounding fire. Spray water for small

fires. For large fires flood with abundant water.

Unsuitable material:

None, but attention should be paid to compatibility with chemicals surrounding.

Protection for firefighters

Specific hazards arising from the chemical

Thermal decomposition can lead to the escape of toxic/corrosive gases and vapours.

Products of combustion

Thermal decomposition products: refer to section 10.

Protective equipment and precautions for firefighters

Keep upwind of fire. Wear full fire fighting turn-out gear (full Bunker gear) and respiratory protection (SCBA).

ACCIDENTAL RELEASE MEASURES

Personal precautions

Provide adequate ventilation. Wear personal protection equipment (Section 8).

Environmental precautions

Do not allow to enter into surface water or drains. Ensure waste is collected and contained.

Methods for containment and cleaning up

Take up mechanically, placing in appropriate containers for disposal or recovery.

Unsuitable material for containment/taking up:

Do not absorb in saw-dust or other combustible absorbents.

Other information

None

HANDLING AND STORAGE

Avoid generation of dust. Provide adequate ventilation. Wear personal protective equipment. Wash hands thoroughly after handling. Do no eat, drink or smoke when using this product. Keep away from flammable, combustible and reducing substances.

Keep/store only in original container. Store in a well-ventilated place. Keep container tightly closed.

Do not store together with:

Combustible substance, reducing agents

Perchlorate containing product - Special handling may apply. See www.dtsc.ca.gov/hazardouswaste/perchlorate and Section 15 for more Information regarding California State regulations.

EXPOSURE CONTROLS/PERSONAL PROTECTION

Particulates Not Otherwise Regulated (PNOR):

Exposure Guldelines

Occupational exposure limits

Sodium nitrate:

No specific occupational exposure limit.

Inert or Nuisance Dust:

mppcf* mg/m

Respirable fraction

15

5 15

Total dust *Millions of particles per cubic foot of air

50

Engineering controls

Use exhaust ventilation to keep airborne concentrations below exposure limits.

Personal Protective Equipment

Eye/face protection

Chemical goggles required all the time.

Skin Protection

Nitrile rubber gloves, over 0.11 mm thickness, > 480 min breakthrough time,

recommended.

Respiratory Protection

Wear respiratory protection, where airborne concentrations are expected to

exceed exposure limits

General Hygiene Considerations

Avoid contact with eyes and skin. Wash hands thoroughly after handling, Have eye-wash facilities immediately available.

Poisoning Toxicology Handbook Generated by CRL™

Sodium Azide

CAS Number 26628-22-8; 12136-89-9

UN Number 1687

Synonyms Azium: Azomide

Use Shell detonators in explosive industry; found as principle agent (350-600 g) for providing nitrogen for the rapid expansion (in 0.05 seconds) of automobile air bags; preservative for laboratory reagents (concentration ~1 mg/mL); nematocide; herbicide

Mechanism of Toxic Action Mucosal irritant; may inhibit oxidative phosphorylation; can cause vasodilitation Adverse Reactions

Cardiovascular: Asystole, hypotension, initial bradycardia followed by tachycardia, chest pain, arrhythmias (atrial/ventricular), myocardial depression, congestive heart failure, vasodilation

Central nervous system: Hypothermia, hyperthermia, headache, agitation, seizures, coma

Dermatologic: Dermal burns

Endocrine & metabolic: Polydipsia, metabolic acidosis

Gastrointestinal: Diarrhea, nausea

Hematologic: Leukocytosis

Neuromuscular & skeletal: Weakness, hyporeflexia, paresthesia Ocular: Photophobia, lacrimation, keratitis, corneal burn, mydriasis

_Respiratory: Hyperventilation, tachypnea, dyspnea, pulmonary edema ಿ 🦼

Miscellaneous: Diaphoresis

Admission Criteria/Prognosis Admit any ingestion >40 mg in adults or any symptomatic patient 2 hours postexposure; any patient with metabolic acidosis should be admitted

Toxicodynamics/Kinetics

Absorption: Inhalation, dermal or ingestion Metabolism: Converted to nitric oxide

Reference Range Postmortem blood levels (following ingestion of sodium azide): 8-262 mg/L

Overdosage/Treatment

Decontamination: Oral: Activated charcoal. Dermal: Flush with water. Inhalation: Administer 100% humidified oxygen. Ocular: Copious irrigation with saline or water

Supportive therapy: I.V. sodium bicarbonate (1-3 mEq/kg) for acidosis; phenobarbital is probably the most effective agent to treat seizures. Hypotension can be treated with crystalloid solution (10-20 mL/kg) and placement in Trendelenburg position. Vasopressors (dopamine or norepinephrine) can be used for resistant cases. The use of sodium nitrite or hyperbaric oxygen is of theoretical benefit, with human data lacking in efficacy.

Enhancement of elimination: Extracorporeal removal is of no benefit. Exchange transfusion does not appear to be beneficial.

Additional Information Fatal oral dose: 13 mg/kg

Oral dose of 0.5 mcg/kg can result in reduction of blood pressure; positive ferric chloride (10% to 20%) test of gastric aspirate can occur (red precipitate)

Rescuer can become mildly toxic (headache, nausea) from expired air or gastric aspirate of sodium azide toxic patients (due to hydrazoic acid)

Odorless, colorless, highly explosive. Specific gravity: 1.846. TLV-ceiling: 0.11 ppm

Byproducts of sodium azide detonation include sodium hydroxide and nitrogen.

Other chemical constituents in automobile air bags include 2,4-dinitrotoluene, boron, potassium nitrate, nitrocellulose and cupric oxide

Facts About Sodium Azide

What sodium azide is

- · Sodium azide is a rapidly acting, potentially deadly chemical that exists as an odorless white solid.
- When it is mixed with water or an acid, sodium azide changes rapidly to a toxic gas with a pungent (sharp) odor. It also
 changes into a toxic gas (hydrazoic acid) when it comes in contact with solid metals (for example, when it is poured into a
 drain pipe containing lead or copper).
- · The odor of the gas may not be sharp enough, however, to give people sufficient warning of the danger.

Where sodium azide is found and how it is used

- Sodium azide is best known as the chemical found in automobile airbags. An electrical charge triggered by automobile impact causes sodium azide to explode and convert to nitrogen gas inside the airbag.
- Sodium azide is used as a chemical preservative in hospitals and laboratories. Accidents have occurred in these settings. In one
 case, sodium azide was poured into a drain, where it exploded and the toxic gas was inhaled (breathed in).
- · Sodium azide is used in agriculture (farming) for pest control.
- Sodium azide is also used in detonators and other explosives.

How you could be exposed to sodium azide

- · Following release of sodium azide into water, you could be exposed to sodium azide by drinking the contaminated water.
- · Following contamination of food with sodium azide, you could be exposed to sodium azide by eating the contaminated food.
- · Following release of sodium azide into the air, you could be exposed by breathing in the dust or the gas that is formed.
- · Sodium azide can also enter the body and cause symptoms through skin contact.
- An explosion involving sodium azide may cause burn injury as well as expose people to the toxic gas, hydrozoic acid.

How sodium azide works

- The seriousness of poisoning caused by sodium azide depends on the amount, route, and length of time of exposure, as well as
 the age and preexisting medical condition of the person exposed.
- Breathing the gas that is formed from sodium azide causes the most harm, but ingesting (swallowing) sodium azide can be toxic as well.
- The gas formed from sodium azide is most dangerous in enclosed places where the gas will be trapped. The toxic gas quickly disperses in open spaces, making it less harmful outdoors.
- · The gas formed from sodium azide is less dense (lighter) than air, so it will rise.
- · Sodium azide prevents the cells of the body from using oxygen. When this happens, the cells die.
- Sodium azide is more harmful to the heart and the brain than to other organs, because the heart and the brain use a lot of oxygen.

Immediate signs and symptoms of sodium azide exposure

- People exposed to a small amount of sodium azide by breathing it, absorbing it through their skin, or eating foods that contain
 it may have some or all of the following symptoms within minutes:
 - · Clear drainage from the nose (gas or dust exposure)
 - · Cough (gas or dust exposure)
 - Dizziness
 - Headache
 - Nausea and vomiting

- Rapid breathing
- · Rapid heart rate
- · Red eyes (gas or dust exposure)
- Restlessness
- Weakness
- Skin burns and blisters (explosion or direct skin contact)
- · Exposure to a large amount of sodium azide by any route may cause these other health effects as well:
 - Convulsions
 - · Low blood pressure
 - · Loss of consciousness
 - Lung injury
 - · Respiratory failure leading to death
 - · Slow heart rate
- · Showing these signs and symptoms does not necessarily mean that a person has been exposed to sodium azide.

What the long-term health effects may be

Survivors of serious sodium azide poisoning may have heart and brain damage.

How people can protect themselves and what they should do if they are exposed to sodium azide

- First, get fresh air by leaving the area where the sodium azide was released. Moving to an area with fresh air is a good way to reduce the possibility of death from exposure to sodium azide.
 - · If the sodium azide release was outside, move away from the area where the sodium azide was released.
 - If the sodium azide release was indoors, get out of the building.
 - If leaving the area that was exposed to sodium azide is not an option, stay as low to the ground as possible, because sodium azide fumes rise.
 - If you are near a release of sodium azide, emergency coordinators may tell you to either evacuate the area or to "shelter in place (http://emergency.cdc.gov/planning/Shelteringfacts.asp)" inside a building to avoid being exposed to the chemical. For more information on evacuation during a chemical emergency, see "Facts About Evacuation (http://emergency.cdc.gov/planning/evacuationfacts.asp)". For more information on sheltering in place during a chemical emergency, see "Facts About Sheltering in Place (http://emergency.cdc.gov/planning/Shelteringfacts.asp)".
 - If you think you may have been exposed to sodium azide, you should remove your clothing, rapidly wash your entire body with soap and water, and get medical care as quickly as possible.
- · Removing your clothing:
 - Quickly take off clothing that may have sodium azide on it. Any clothing that has to be pulled over the head should be cut off the body instead of pulled over the head.
 - If you are helping other people remove their clothing, try to avoid touching any contaminated areas, and remove
 the clothing as quickly as possible.
- Washing yourself:
 - As quickly as possible, wash any sodium azide from your skin with large amounts of soap and water. Washing with soap and water will help protect people from any chemicals on their bodies.
 - If your eyes are burning or your vision is blurred, rinse your eyes with plain water for 10 to 15 minutes. If you wear contacts, remove them and put them with the contaminated clothing. Do not put the contacts back in your eyes (even if they are not disposable contacts). If you wear eyeglasses, wash them with soap and water. You can put your eyeglasses back on after you wash them.
- Disposing of your clothes:
 - After you have washed yourself, place your clothing inside a plastic bag. Avoid touching contaminated areas of the clothing. If you can't avoid touching contaminated areas, or you aren't sure where the contaminated areas are, wear rubber gloves or put the clothing in the bag using tongs, tool handles, sticks, or similar objects. Anything that touches the contaminated clothing should also be placed in the bag. If you wear contacts, put them in the plastic bag, too.
 - Seal the bag, and then seal that bag inside another plastic bag. Disposing of your clothing in this way will help
 protect you and other people from any chemicals that might be on your clothes.
 - When the local or state health department or emergency personnel arrive, tell them what you did with your clothes. The health department or emergency personnel will arrange for further disposal. Do not handle the plastic bags yourself.
 - For more information about cleaning your body and disposing of your clothes after a chemical release, see "Chemical Agents: Facts About Personal Cleaning and Disposal of Contaminated Clothing (http://emergency.cdc.gov/planning/personalcleaningfacts.asp)".

- If someone has ingested sodium azide, do not induce vomiting or give fluids to drink. Also, if you are sure the person has ingested sodium azide, do not attempt CPR using mouth to mouth breathing. Performing CPR on someone who has ingested sodium azide could expose you to the chemical.
- When sodium azide is ingested, it mixes with stomach acid and forms the toxic gas, hydrozoic acid. If a person who has ingested sodium azide is vomiting, isolate and stay away from the stomach contents (vomit) to avoid
- Do not pour substances containing sodium azide (such as food, water, or vomit) in the drain, because the drain can
- · Seek medical attention right away.

How sodium azide poisoning is treated

Sodium azide poisoning is treated with supportive medical care in a hospital setting. No specific antidote exists for sodium azide poisoning. The most important thing is for victims to seek medical treatment as soon as possible.

How you can get more information about sodium azide

You can contact one of the following:

- Regional poison control center: 1-800-222-1222
- Centers for Disease Control and Prevention
 - Public Response Hotline (CDC)
 - 800-CDC-INFO
 - 888-232-6348 (TTY)
 - E-mail inquiries: cdcinfo@cdc.gov (mailto:cdcinfo@cdc.gov)
- · Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH), Pocket Guide to Chemical Hazards (http://www.cdc.gov/niosh/npg/npgd0560.html).
- Page last reviewed April 10, 2013
- Page last updated April 10, 2013
- Content source: National Center for Environmental Health (NCEH) (http://www.cdc.gov/nceh/) /Agency for Toxic Substances and Disease Registry (ATSDR) (http://www.atsdr.cdc.gov/)

Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333, USA 800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO



What all rescuers should know - Chemical propellant for airbags can kill!

Report by Len Watson

Sodium Azide (NaN₃) airbag propellant is a growing health hazard and environmental problem -

Vehicle Airbags use a chemical compound that is so toxic that even small amounts can kill. Yet tons and tons of Sodium Azide (NaN₃) are routinely transported around the longitude and latitude of the world. Additionally scrapped airbags sit like environmental time bombs in the myriad of scrap yards that we see in most communities.

On March 26, 2005 at a national meeting of the American Chemical Society in San Francisco, atmospheric scientist Eric A. Betterton (University of Arizona) said 'scientists really don't know where or how all this Sodium Azide will inevitably wreak greatest environmental havoc'. For several years now, both he and his undergraduates have been carrying out experiments to gain a greater understanding.

Although Sodium Azide is already used in many industrial products, such as explosives, detonators, anticorrosion solutions, broad-spectrum biocides and airline safety chutes, with the advancement of passive vehicle safety systems a much larger threat to our environment has emerged over the last 15 years.

Betterton stated -

"As the demand for airbags increases, and as vehicle fleets age over the next few decades, the amount of Sodium Azide that could potentially be released to the environment will greatly exceed the approximated 5 million kilograms (11 million pounds) that has already been incorporated into airbag inflators in the United States alone."

"Given the huge surge in production, there exists a greatly increased potential for significant accidental spills and subsequent human and environmental exposure to this material."

Sodium Azide

Sodium Azide (NaN₃) looks like common table salt but is every bit as powerful a poison as Sodium Cyanide. Even in minute amounts it can kill everything from bacteria and fungi to animals and humans.

Ingesting or adsorbing as little as 50 milligrams (less than two-thousandths of an ounce) can cause the average adult to collapse into a coma-like state within five minutes. Blood pressure will drop and the heart will become tachycardic. Ingest a few grams, and death can occur in as little as 30 minutes.

Studies as far back as 1970 show that at 10 parts per million in the soil, Sodium Azide kills or degrades the seeds of many plants. Betterton noted that at 200 ppm, it not only sterilises the soil - but also changes soil chemistry, killing all soil bacteria and fungi.

Little is known about the environmental effects of Sodium Azide. However what is known is that Sodium Azide is water-soluble. Betterton states that "Spills could possibly migrate into the water table via sewers, streams, lakes, and groundwater systems,".

The compound when wet protonates volatile Hydrazoic Acid, a potential threat to rescuers, vehicle recovery agents and even sanitation workers and others that may come in contact with the Acid or Hydrazoic Acid gas.


Betterton and his students tested how readily it oxidises when exposed to some environmental oxidants that may be found in water, such as Hydrogen Peroxide, an ingredient in natural rainwater, and ozone, a very powerful oxidant in the atmosphere.

Oxidisation is just one way Sodium Azide degrades in the environment. Betterton's studies also show that Sodium Azide combines readily with water to form Hydrazoic Acid. The "Henry's Law constant" for Hydrazoic Acid, or the ratio of how much Hydrazoic Acid that remains in solution and how much will be released as highly toxic Hydrazoic Acid gas into the atmosphere. The Henry's Law constant identifies that much more of the acid is released as gas into the atmosphere than remains in water.

Rescue Implications -

The wide use of Sodium Azide as a means of propellant to inflate airbags in passive restraint systems is readily accepted as the motor industry standard. Tiny tablets of Sodium azide are packed into a 50mm-diameter metal canister inside the airbag module. The driver-side airbag inflator holds about 50 grams of Sodium Azide. The passenger-side airbag inflator is about 150mm in diameter and holds in the region of 200 grams to inflate the larger front passenger bag. Moreover and perhaps much more prevalent, seat airbags and seatbelt pretensioners can also contain Sodium Azide.

This knowledge gives immediate recognition to the risk that rescuers face when performing certain extrication evolutions in releasing trapped vehicle occupants. Apart from the obvious risk of deploying undeployed systems as the wreckage is cut away, rescuers are also confronted with the possibility of inadvertent cutting through a module releasing Sodium Azide. The highest probability of this would appear to exist when removing the side of the vehicle.



Cutting away the centre post complete with the rear door on the 4 door car usually necessitates cutting into the base of the centre post. To inadvertently cut through the pretensioner unit can liberate the Sodium Azide and powder the pellets in the process. This becomes more prevalent where a 'combi' tool is used to cut the base of the centre post.

Release of Sodium Azide -

A similar situation also exists where the 1/4 panel on a 2 door car or coupe needs to be cut away to release a rear seat occupant. The hydraulic cutter has sufficient power to cut through the pretensioner's cartridge and, where it does not deploy under the cutting pressure, liberate its contents.



Potentially this situation could be exacerbated if it were raining at the time or, if the powdered residue on the cutter's blades were to fall into open wounds or the dust inhaled on a windy day.

Of course avoiding the pretensioner in the first place would appear to be the answer; but 'what if' still identifies a valid training need.



'Side removal' performed using a combi tool carries the highest risk of inadvertently cutting through the pretensioner module.

We must also consider that in the process of extricating people from crashed vehicles rescuers will cut away doors, roofs and remove seats. Some doors and seats which, on many occasions, will increasingly incorporate undeployed airbags; when removed will become a hazard putting investigating officers, recovery agents and reclaimed parts and scrap technicians at risk. This in time promises to become a serious situation generating thousands of door, seat and roof units year on year in the UK alone.

End of life airbag

Every airbag has a rated life expectancy in which it should perform as intended. Most manufacturers state 10 some state 15 years. As the module matures and its life cycle reached and exceeded, pellets will suffer from fatigue and crumble. The increased surface area of degraded propellant will give rise to faster ignition with much greater deployment force that can burst the airbag.

With age the integrity of the hermetic container can fail. Sodium Azide is hydroscopic and atmospheric water vapour can leak through the inner foil and the squib seal and corrode contacts and the container itself, which in turn can leak Hydrozoic Acid.

End of life vehicle processing (Depollution).

From the 2.3 million End-of-Life Vehicles (ELV) in the UK each year, scrap yard technicians increasingly remove airbags and store them. Some are left in cars as they stand degrading in the lot. Some are crushed and the airbag canister can burst open, spilling Sodium Azide and generating dust or Hydrazoic Acid.

Airbag storage is a problematic issue for many organisations. Any airbag store needs to meet a minimum specification and be licensed. The store must be securable, weatherproof and clearly labelled with the appropriate warning signs. A method of stock control / tracking of contents is also required. Licences are normally granted by the local Trading Standards Explosives Officer. Currently, it is illegal to attempt to dispose of <u>live</u> airbags in any UK landfill site.

With a view to control the ELV a directive was passed into European law in October 2000 and was due to be transposed into national law in all Member States by 21 April 2002. Unfortunately this was delayed (as in most other Member States), the UK is currently in the process of introducing the remaining provisions. However it is their aim to reduce, or prevent, the amount of waste produced from ELVs and increase the recovery and recycling of ELVs that do arise. Moreover they only state that airbags and pretensioners must be removed or deployed before depollution. How they actually enforce and police this is quite another matter.

No one currently knows the lifetime of Azide in the atmosphere and what the accumulative effect may be. What we do know is that Sodium Azide is a very dangerous and volatile substance and one that must be treated with a high degree of respect.

Security implication

A security warning would also seem to be in order. How long have we got before unscrupulous people realise the potential this readily available chemical holds for mayhem and terrorism? It takes little imagination to visualise the possibilities that could exist. Such an easily acquired chemical with high reactivity that changes its state so readily must give rise to serious security implications. Fortunately its saving grace is in the fact that it could prove lethal to reclaim from its sealed container.

Facts About Sodium Azide - What sodium azide is

- Sodium azide is a rapidly acting, potentially deadly chemical that exists as an odourless white solid.
- When it is mixed with water or an acid, sodium azide changes rapidly to a
 toxic gas with a pungent (sharp) odour. It also changes into a toxic gas when
 it comes in contact with solid metals (for example, when it is poured into a
 drain pipe containing lead or copper).
- The odour of the gas may not be sharp enough, however, to give people sufficient warning of the danger.

- o Restlessness
- o Dizziness
- o Weakness
- o Headache
- o Nausea and vomiting
- o Rapid heart rate
- o Red eyes (gas or dust exposure)
- o Clear drainage from the nose (gas or dust exposure)
- o Cough (gas or dust exposure)
- o Skin burns and blisters (explosion or direct skin contact)
- Exposure to a large amount of sodium azide by any route may cause these other health effects as well:
 - Convulsions
 - Low blood pressure
 - Slow heart rate
 - o Loss of consciousness
 - o Lung injury
 - o Respiratory failure leading to death
- Showing these signs and symptoms does not necessarily mean that a person has been exposed to sodium azide.

What the long-term health effects may be

Survivors of serious sodium azide poisoning may have heart and brain damage.

How people can protect themselves and what they should do if they are exposed to sodium azide

- First, get fresh air by leaving the area where the sodium azide was released.
 Moving to an area with fresh air is a good way to reduce the possibility of death from exposure to sodium azide.
 - o If the sodium azide release was outside, move away from the area where the sodium azide was released.
 - o If the sodium azide release was indoors, get out of the building.
 - If leaving the area that was exposed to sodium azide is not an option, stay as low to the ground as possible, because sodium azide fumes rise.
 - o If you are near a release of sodium azide, emergency coordinators may tell you to either evacuate the area or to "shelter in place" inside a bullding to avoid being exposed to the chemical. For more information on evacuation during a chemical emergency, see "Facts About Evacuation". For more information on sheltering in place during a chemical emergency, see "Facts About Sheltering in Place".
 - o If you think you may have been exposed to sodium azide, you should remove your clothing, rapidly wash your entire body with soap and water, and get medical care as quickly as possible.

Removing your clothing:

- Quickly take off clothing that may have sodium azide on it. Any clothing that has to be pulled over the head should be cut off the body instead of pulled over the head.
- o If you are helping other people remove their clothing, try to avoid touching any contaminated areas, and remove the clothing as quickly as possible.

Where sodium azide is found and how it is used

- Sodium azide is best known as the chemical found in automobile airbags. An
 electrical charge triggered by automobile impact causes sodium azide to
 explode and release nitrogen gas inside the airbag.
- Sodium azide is used as a chemical preservative in hospitals and laboratories. Accidents have occurred in these settings. In one case, sodium azide was poured into a drain, where it exploded and the toxic gas was inhaled (breathed in).
- Sodium azide is used in agriculture (farming) for pest control.
- Sodium azide is also used in detonators and other explosives.

How you could be exposed to sodium azide

- Following release of sodium azide into water, you could be exposed to sodium azide by drinking the contaminated water.
- Following contamination of food with sodium azide, you could be exposed to sodium azide by eating the contaminated food.
- Following release of sodium azide into the air, you could be exposed by breathing in the dust or the gas that is formed.
- Sodium azide can also enter the body and cause symptoms through skin contact.
- An explosion involving sodium azide may cause burn injury as well as expose people to the toxic gas, hydrozoic acid.
- CDC has received no reports of sodium azide exposure following automobile airbag deployment.

How sodium azide works

- The seriousness of poisoning caused by sodium azide depends on the amount, route, and length of time of exposure, as well as the age and preexisting medical condition of the person exposed.
- Breathing the gas that is formed from sodium azide causes the most harm, but ingesting (swallowing) sodium azide can be toxic as well.
- The gas formed from sodium azide is most dangerous in enclosed places where the gas will be trapped. The toxic gas quickly disperses in open spaces, making it less harmful outdoors.
- The gas formed from sodium azide is less dense (lighter) than air, so it will rise.
- Sodium azide prevents the cells of the body from using oxygen. When this happens, the cells die.
- Sodium azide is more harmful to the heart and the brain than to other organs, because the heart and the brain use a lot of oxygen.

Immediate signs and symptoms of sodium azide exposure

- People exposed to a small amount of sodium azide by breathing it, absorbing it through their skin, or eating foods that contain it may have some or all of the following symptoms within minutes:
 - o Rapid breathing

Washing yourself:

- As quickly as possible, wash any sodium azide from your skin with large amounts of soap and water. Washing with soap and water will help protect people from any chemicals on their bodies.
- o If your eyes are burning or your vision is blurred, rinse your eyes with plain water for 10 to 15 minutes. If you wear contacts, remove them and put them with the contaminated clothing. Do not put the contacts back in your eyes (even if they are not disposable contacts). If you wear eyeglasses, wash them with soap and water. You can put your eyeglasses back on after you wash them.

Disposing of your clothes:


- After you have washed yourself, place your clothing inside a plastic bag. Avoid touching contaminated areas of the clothing. If you can't avoid touching contaminated areas, or you aren't sure where the contaminated areas are, wear rubber gloves or put the clothing in the bag using tongs, tool handles, sticks, or similar objects. Anything that touches the contaminated clothing should also be placed in the bag. If you wear contacts, put them in the plastic bag, too.
- Seal the bag, and then seal that bag inside another plastic bag.
 Disposing of your clothing in this way will help protect you and other people from any chemicals that might be on your clothes.
- When the local or state health department or emergency personnel arrive, tell them what you did with your clothes. The health department or emergency personnel will arrange for further disposal. Do not handle the plastic bags yourself.
- o For more information about cleaning your body and disposing of your clothes after a chemical release, see "Chemical Agents: Facts About Personal Cleaning and Disposal of Contaminated Clothing".
- o If someone has ingested sodium azide, do not induce vomiting or give fluids to drink. Also, if you are sure the person has ingested sodium azide, do not attempt CPR. Performing CPR on someone who has ingested sodium azide could expose you to the chemical.
- When sodium azide is Ingested, it mixes with stomach acid and forms the toxic gas, hydrozoic acid. If a person who has ingested sodium azide is vomiting, isolate and stay away from the stomach contents (vomit) to avoid exposure to the toxic gas.
- Do not pour substances containing sodium azide (such as food, water, or vomit) in the drain, because the drain can explode and cause serious harm.
- Seek emergency medical attention right away and explain what has happened.

How sodium azide poisoning is treated

Sodium azide poisoning is treated with supportive medical care in a hospital setting. No specific antidote exists for sodium azide poisoning. The most important thing is for victims to seek medical treatment as soon as possible.

How you can get more information about sodium azide You can contact one of the following:

- Regional poison control centre USA: 1-800-222-1222
- Centres for Disease Control and Prevention
 - o Public Response Hotline (CDC)



среека

olong gal

· 9 Avenuer Shelley Goodall

Write a comment...

Fike · Reply · January 6 at 1:50pm Richard Goodall Well we are Goodall's Like · Reply · January 6 at 1:42pm like the missing link somedays)!

Like · Reply · January 6 at 1:25pm

Comment


Richard Goodall What are u doing pinching your

Share

1ib3

Add Location

neuro an pulmonary dra.next so who knows. Feel are fine too. So now they are sending me to the deared by the heart Dr no trouble there an kidneys insides feel like they are being squeezed! Been this happens the blood pressure rolls an my until winter time. So who knows all I know is when rosacea either, All I know is this never happens Shelley Goodall No not pinching my cheeks an no





4/30/2016



Shelley Goodall January 26 ·

Okay here is my face again RED RASH WTH IS THIS? I have date an I am not going out looking like this. At the do Dr's now somebody better figure this out. I'm tired of being the missing link!!!!

Tag Photo

Add Location

Edit

Like

Comment Share



Mandykay Squires-Bly Maybe it's a make up or maybe something you also maybe something you ate have they tested for celiac disease

Like · Reply · January 26 at 1:32pm



Robin Goodall Lagree with Manda make up or something you are eating.


Like · Reply · January 26 at 3:39pm





Write a comment...

4/30/2016













Shelley Goodall March 12 ·

Not to bad considering I had a stroke. But believe you me I am very very gratful to God for sparing my life yet again. I don't deserve it but I guess God has other things in store for me. Plus I get to stay around and torture you good people. LMAO! Love ya, Shell





4/30/2016



Write a comment...